- ISIN
- CA98400H1029
- CUSIP
- 98400H102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 15, 2015
Highlights
- Market Cap
- $67.99M
- Enterprise Value
- -$47.47M
- EPS (TTM)
- -$1.32
- Gross Profit (TTM)
- -$805.00K
- EBITDA (TTM)
- -$42.42M
- Year Range
- $2.09 - $3.61
- ROA (TTM)
- -28.72%
- ROE (TTM)
- -29.75%
- Avg. Volume (1M)
- 43K
- Avg. Volume Value (1M)
- $97.91K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
XBIT Performance Chart
XBiotech Inc. (XBIT) is down 6.7% since the beginning of the year. At $2 per share, XBIT is trading 38.2% below its 52-week high of $4. Investors who bought $1,000 worth of XBIT shares 5 years ago would now be looking at an investment worth $138.
Loading charts...
Compare this symbol against anything
Returns By Period
XBiotech Inc. (XBIT) has returned -6.69% so far this year and -21.75% over the past 12 months. Over the last ten years, XBIT has returned -15.23% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
XBiotech Inc.
- 1D
- -0.45%
- 1M
- -3.04%
- 6M
- -11.16%
- YTD
- -6.69%
- 1Y
- -21.75%
- 3Y*
- -25.25%
- 5Y*
- -32.74%
- 10Y*
- -15.23%
- ALL TIME*
- -17.59%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
XBIT Monthly Returns History
Based on dividend-adjusted daily data since Apr 15, 2015, XBIT's average daily return is +0.04%, while the average monthly return is +0.32%. At this rate, an investment would double in approximately 18.1 years.
Historically, 45% of months were positive and 55% were negative. The best month was Dec 2019 with a return of +62.5%, while the worst month was Dec 2024 at -48.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, XBIT closed higher 46% of trading days. The best single day was Dec 9, 2019 with a return of +75.4%, while the worst single day was Jun 9, 2017 at -66.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.02% | -9.96% | 3.98% | 9.36% | -5.84% | -4.96% | -3.04% | -6.69% | |||||
| 2025 | -12.41% | 1.73% | -7.95% | -6.17% | -6.25% | 4.21% | -2.36% | 8.97% | -15.82% | -11.65% | -3.40% | 5.29% | -39.49% |
| 2024 | 14.75% | 36.38% | 29.87% | -5.66% | -5.48% | -29.10% | 50.19% | -17.10% | 20.78% | -6.08% | 4.82% | -48.09% | -1.25% |
| 2023 | 23.93% | -22.76% | 2.68% | -0.29% | 48.11% | 16.58% | -15.32% | -2.19% | -16.26% | 1.46% | -6.22% | 2.04% | 13.96% |
| 2022 | -3.23% | -8.45% | -12.37% | -10.19% | -29.12% | 2.36% | -8.17% | -22.44% | -9.73% | -3.04% | -7.69% | 8.33% | -68.46% |
| 2021 | 19.68% | 1.44% | -9.63% | -0.52% | 1.00% | -4.00% | 13.53% | -1.42% | -18.91% | 13.20% | -13.92% | -11.81% | -17.46% |
Benchmark Metrics
XBiotech Inc. has an annualized alpha of -0.23%, beta of 0.89, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since April 15, 2015.
- This stock participated in 142.75% of S&P 500 Index downside but only 16.21% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.23%
- Beta
- 0.89
- R²
- 0.04
- Upside Capture
- 16.21%
- Downside Capture
- 142.75%
Return for Risk
Risk / Return Rank
XBIT ranks 23 for risk / return — above 23% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for XBiotech Inc. (XBIT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XBIT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.91 | ||
| Sortino ratioReturn per unit of downside risk | -2.52 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.25 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.59 | 2.00 | -2.59 |
| Martin ratioReturn relative to average drawdown | -0.80 | 8.49 | -9.29 |
Dividends
Dividend History
XBiotech Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.50 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 22.46% |
Monthly Dividends
The table displays the monthly dividend distributions for XBiotech Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $2.50 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.50 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the XBiotech Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the XBiotech Inc. was 92.67%, occurring on Sep 11, 2018. The portfolio has not yet recovered.
The current XBiotech Inc. drawdown is 91.78%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-92.67%Sep 2018 | 3y 4mo | — | 11y 3moApr 2015 - now | Rate-hike selloffLate 2018 |
-2.32%Apr 2015 | 1d | 1d | 1dApr 2015 - Apr 2015 | — |
Drawdown Indicators
| XBIT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.67% | -56.78% | -35.89% |
Max Drawdown (1Y)Largest decline over 1 year | -39.43% | -9.10% | -30.33% |
Max Drawdown (3Y)Largest decline over 3 years | -78.56% | -18.90% | -59.66% |
Max Drawdown (5Y)Largest decline over 5 years | -87.07% | -25.43% | -61.64% |
Max Drawdown (10Y)Largest decline over 10 years | -90.13% | -33.92% | -56.21% |
Current DrawdownCurrent decline from peak | -91.78% | -1.58% | -90.20% |
Average DrawdownAverage peak-to-trough decline | -70.38% | -10.70% | -59.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.93% | 2.14% | +26.79% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of XBiotech Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how XBiotech Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XBIT in comparison with other companies in the Biotechnology industry. Currently, XBIT has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with XBIT
Add XBiotech Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with XBIT